The recent stock transaction involving David Aaron Lehman, General Counsel at Pulmonx Corp. (NASDAQ:LUNG), draws attention to executive activity within the company. On June 1, 2026, Mr. Lehman executed a sale of common stock shares valued at $22,474.
The specific details of this divestiture indicate that 14,594 shares of Pulmonx's common stock were sold at a rate of $1.54 per share. These sales transactions were executed to satisfy tax withholding obligations resulting from the vesting of Restricted Stock Units (RSUs). The RSU grants covered a period spanning multiple dates between March 1, 2023, and March 2, 2026.
The sale price of $1.54 is noted to be in close proximity to the stock's current trading price of $1.52. This pricing context is significant given that the common stock has experienced a decline of 52% over the preceding year. While some analysis, such as that provided by InvestingPro, suggests the stock may currently appear undervalued due to its Fair Value estimate pointing toward potential upside, other insights present a contrasting view.
The company's financial health is viewed through multiple lenses. On one hand, Pulmonx maintains liquid assets that are stated to exceed its short-term obligations. However, the same analysis points out that the corporation is rapidly utilizing cash reserves and remains in an unprofitable operational state. Following Mr. Lehman's recent sales, his direct holdings of Pulmonx Corp common stock total 376,161 shares.
In parallel developments, Pulmonx Corporation released its financial outcomes for the first quarter of 2026. The reported figures presented a mixed picture for investors assessing the company's operational performance and financial stability.
Specifically, the company surpassed market expectations regarding profitability, reporting an earnings per share (EPS) of -$0.33. This figure was better than the projected estimate of -$0.35. However, this positive development in earnings was offset by a shortfall in top-line revenue. Pulmonx's actual revenue reached $20.6 million, falling short of the anticipated $22.65 million.
This discrepancy between stronger-than-expected EPS and lower-than-anticipated revenue has become a key focus for both investors and industry analysts. The decline in revenue represents a notable concern despite the improvement seen in earnings per share. These combined developments underscore the challenges that Pulmonx is currently navigating in meeting broader revenue expectations. Consequently, observers are expected to maintain close scrutiny of Pulmonx’s overall financial standing moving forward.